α-酸通过调节PPARγ/NF-κB介导的神经炎症来缓解与年龄相关的认知衰退
Zhenyuan Zhang1, Cong Zhang2, Yuan Zhao3
1Department of Geriatrics, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei 050000, PR China; Department of Neurology, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei 050000, PR China.
Experimental gerontology
|October 12, 2025
概括
阿尔法-酸 (LA) 通过PPARγ/NF-κB通路减少神经炎症来改善衰老中的认知功能. 这项研究表明LALA.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 衰老研究研究 衰老研究
背景情况:
- 与年龄相关的认知能力下降与慢性神经炎症有关.
- 阿尔法-酸 (LA) 是一种潜在的认知增强剂.
- 过氧体增殖器激活受体玛 (PPARγ) /核因子卡帕B (NF-κB) 途径与神经炎症有关.
研究的目的:
- 调查LA是否可以改善与衰老相关的认知障碍.
- 为了确定LA是否通过PPARγ/NF-κB途径调节神经炎症,在体内和体外.
主要方法:
- 年龄大于C57BL/6的小鼠接受了LA (100 mg/kg/天) 的治疗,持续了8周.
- 行为测试 (T迷宫),免疫光,PCR和西班牙黑斑被用来评估认知功能和神经炎症.
- 在体外,D-银糖诱导的BV2细胞模拟了衰老,并进行了生命力和通路分析.
主要成果:
- 在老年小鼠中,LA显著改善了认知功能.
- 在海马体中,LA抑制了微质分裂,星细胞分裂和促炎性细胞因子.
- LA上调了PPARγ并抑制了NF-κB酸化,这种效应在体外得到证实,并被PPARγ抗剂阻断.
结论:
- 通过抑制PPARγ/NF-κB来调节神经炎症,LA可以缓解与年龄相关的认知缺陷.
- 劳动力证明了治疗潜在的认知衰退在衰老.
- PPARγ/NF-κB轴在神经炎症调节中发挥着关键作用.
相关概念视频
Alzheimer's Disease: Treatment
822
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
822
Atherosclerosis III: Management
319
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
319
Aging
600
Aging is a complex biological phenomenon influenced by various processes that affect cellular and systemic functions. Several prominent theories attempt to explain its mechanisms, highlighting cellular limitations, oxidative damage, and hormonal changes as central factors in aging.
Cellular Clock Theory
The cellular clock theory posits that the human lifespan is closely tied to the finite capacity of cells to divide, a phenomenon governed by telomeres, which are protective caps at the ends of...
Cellular Clock Theory
The cellular clock theory posits that the human lifespan is closely tied to the finite capacity of cells to divide, a phenomenon governed by telomeres, which are protective caps at the ends of...
600
Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
558
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
558
Pharmacodynamics in Geriatric Patients: Effects of Age
187
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
187
